Study guide
12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal)
Certified Nuclear Medicine Technologist CNMT
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current CNMT Exam Facts 1.2 How to Use This Guide
2 Radiation Physics Fundamentals
2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles
3 Biological Effects & ALARA
3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring
4 NRC & Regulatory Compliance
4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records
5 Generators & Kit Preparation
5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control
6 Tc-99m Diagnostic Agents
6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells
7 Non-Tc Diagnostic & PET Agents
7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents
8 Therapeutics, Adjuncts & Administration
8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents
9 Non-Imaging Instrumentation
9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment
10 Imaging Systems & Quality Control
10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization
11 Pulmonary, Bone, Oncology & Infection Imaging
11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures
12 Renal, Endocrine & Hematopoietic Imaging
12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique
13 Cardiovascular Procedures
13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing
14 GI, CNS, Therapy & Hybrid CT Procedures
14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency
15 Patient Care & Clinical Workflow
15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis
12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal)
Key Takeaways Explain This Topic AI
I-123 NaI is preferred for diagnostic thyroid morphology; Tc-99m pertechnetate shows trapping only (not organification); I-131 is used for uptake measurements and diagnostic/therapeutic whole-body pathways at very different activities
Thyroid cancer whole-body surveys use diagnostic I-123 or low-activity I-131 with TSH stimulation (thyroid hormone withdrawal or rhTSH), low-iodine diet, and strict separation from therapy-level I-131 doses
Parathyroid adenoma imaging classically uses Tc-99m sestamibi dual-phase washout and/or pertechnetate or I-123 subtraction; SPECT/SPECT-CT localizes ectopic or multigland disease
Adrenal/sympathetic tumor imaging uses I-123 MIBG (norepinephrine analog) with mandatory thyroid blockade and interfering-medication holds; NP-59 is a historical cholesterol-analog adrenocortical agent
High-yield traps: recent iodinated contrast or amiodarone suppressing uptake, skipped thyroid blockade for MIBG/free iodide, dual-phase sestamibi false positives from thyroid nodules, and confusing scan-dose vs therapy-dose radioiodine
Last updated: August 2026
12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal)
Quick Answer: Thyroid: I-123 (preferred diagnostic imaging) vs Tc-99m pertechnetate (trapping only) vs I-131 (uptake / whole-body / therapy dose tiers). Parathyroid: sestamibi dual-phase ± subtraction , finish with SPECT/CT . Adrenal/sympathetic: I-123 MIBG + thyroid blockade; know NP-59 as legacy cortical imaging. Prep (iodine load, meds, TSH, blockade) makes or breaks the study.
- Thyroid Imaging and Uptake
- Physiology review
Follicular cells trap iodide (and pertechnetate) via the sodium-iodide symporter (NIS) . Organification incorporates iodine into thyroglobulin/hormone pathways— I-123/I-131 participate; Tc-99m pertechnetate is trapped but not organified . Salivary glands and gastric mucosa also show NIS-related activity.
Agent What it shows Typical diagnostic use
I-123 NaI Trapping + organification; excellent 159 keV imaging Morphology, nodules, uptake, preferred diagnostic scan
Tc-99m pertechnetate Trapping map only Quick thyroid morphology when iodine unavailable; discordant nodule workups
I-131 NaI (low activity) Uptake quantification; delayed whole-body capability Uptake %; diagnostic whole-body cancer survey
Nodule language (exam favorites)
Pattern Teaching meaning
Hot (hyperfunctioning) nodule Suppresses surrounding tissue; lower cancer probability but still manage clinically
- Cold nodule Decreased function; higher concern—correlate ultrasound/FNA
- Discordant nodule Hot on pertechnetate, cold on radioiodine → failed organification concern
- Uptake measurement
A neck probe or camera ROI measures percent uptake at protocol times (commonly 4–6 h and/or 24 h for iodine). Elevated uptake supports hyperthyroidism patterns (Graves, toxic nodule) when matched to labs; low uptake with thyrotoxicosis suggests thyroiditis or exogenous hormone. Recent iodinated IV contrast, amiodarone, iodine antiseptics, or high-iodine diet suppress measured uptake—document the exposure date.
Patient prep for diagnostic thyroid studies
- Prep item Reason
- Hold levothyroxine / liothyroxine or antithyroid drugs per order Alters uptake and TSH drive
- Avoid recent iodinated contrast (weeks–months effect) Floods iodine pool
- Pregnancy/breastfeeding policies Absolute safety gates
- NPO briefly for oral capsule only if protocol requires Consistent absorption
- Whole-Body Survey for Thyroid Metastases
After near-total thyroidectomy for differentiated thyroid cancer, diagnostic whole-body imaging maps remnant and iodine-avid mets (neck nodes, lungs, bone).
- Element Teaching standard
- Tracers I-123 whole-body or diagnostic I-131 (often ~1–5 mCi range—protocol/regulatory dependent)
- TSH stimulation Thyroid hormone withdrawal (hypothyroid TSH rise) or rhTSH injections
- Low-iodine diet Usually ~1–2 weeks before dosing for surveys/therapy planning
- Imaging times I-123 often ~24 h; I-131 diagnostic may include 48–72 h views
- Therapy I-131 Much higher activity under written directive —never call a therapy dose a “scan dose”
Stunning (high-yield): larger diagnostic I-131 activities may reduce subsequent therapy uptake—many centers prefer I-123 surveys or minimize diagnostic I-131. Follow local protocol.
Traps: physiologic salivary/stomach/bowel/bladder activity; urine or saliva contamination; lactation breast uptake—survey gown/skin for unexpected foci.
Parathyroid Imaging
Primary hyperparathyroidism workups seek a hyperfunctioning adenoma (less often hyperplasia or carcinoma) before minimally invasive surgery.
Dual-phase sestamibi
Tc-99m sestamibi is taken up by both thyroid and abnormal parathyroid tissue (mitochondria-rich adenomas). Early images (~10–15 min) show thyroid + parathyroid; delayed images (~1.5–2.5 h) rely on faster thyroid washout so adenoma persists (“differential washout”).
- Method Idea
- Dual-phase sestamibi Early vs delayed persistence at adenoma site
- Subtraction Sestamibi minus Tc-99m pertechnetate or I-123 thyroid map isolates parathyroid focus
- SPECT / SPECT-CT Depth, ectopic mediastinal glands, multigland disease, anatomic roadmap
Typical adult activity is often ~20–25 mCi sestamibi IV (lab-specific). SPECT/CT is preferred when available for surgical localization.
Traps: thyroid nodules can retain sestamibi (false positive); small hyperplastic glands may be missed (false negative); recent IV contrast CT is complementary but not a substitute for functional localization. Always correlate calcium, PTH, and ultrasound.
- Adrenal Imaging Concepts
- I-123 MIBG (iobenguane)
MIBG is a norepinephrine analog taken up by the norepinephrine transporter into adrenergic tissue— pheochromocytoma, paraganglioma, neuroblastoma , and related tumors. Thyroid blockade (SSKI, Lugol’s, or perchlorate per protocol) is mandatory. Hold interfering drugs (selected antidepressants, labetalol, sympathomimetics, cocaine, others per insert) to avoid false-negative studies. Imaging typically includes 24-hour planar ± SPECT/CT; adult activity often ~10 mCi IV order of magnitude.
NP-59 (historical adrenocortical agent)
I-131 NP-59 (iodomethylnorcholesterol) is a cholesterol analog historically used to image the adrenal cortex (e.g., adenoma vs hyperplasia patterns in hyperaldosteronism/Cushing workups) with multi-day imaging and dexamethasone suppression variants. Modern practice often favors CT/MRI and venous sampling, but CNMT items may still expect: cortical cholesterol pathway , multi-day imaging , and dexamethasone suppression protocol concept . Do not confuse NP-59 (cortex) with MIBG (medulla/sympathetic).
- Pathway Agent class Target
- Adrenal medulla / sympathetic tumors MIBG NET uptake storage granules
- Adrenal cortex (legacy) NP-59 Cholesterol analog uptake
- Endocrine Prep and Trap Matrix
- Study Must-do prep Classic failure mode
- Thyroid uptake/scan No recent iodine load; correct med holds Falsely low uptake after contrast/amiodarone
Cancer whole-body I-123/I-131 TSH stimulation + low-iodine diet Residual diet iodine → poor lesion visualization
- Parathyroid sestamibi Early + delayed ± SPECT/CT; know thyroid disease Hot thyroid nodule called “adenoma”
- MIBG Thyroid blockade + med reconciliation Free iodide in thyroid; drug-related false negative
Selection cheat sheet: morphology with low dose → I-123 ; trapping-only quick look → pertechnetate ; iodine-avid cancer map → stimulated whole-body iodine ; PTH adenoma localization → sestamibi SPECT/CT ; pheo/neuroblastoma → MIBG .